CD8A and melanoma: Collectively, the more robust CD4+ and CD8+ T cell populations and infiltration to tumor sites of the Per1/2−/− mice suggests that clock-regulated immune function plays an important role in sensitizing melanoma tumors to cisplatin treatment.